What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.30%
Annual Rate
CNY 0.16Paid semi-annual
Payout Ratio
11.7%Sustainable
Last Ex-Dividend
Jul 9, 2026
The reported statements, read against the company's own industry.
What stands out
Earnings significantly exceed cash generation
Financials view
Market Capitalization
3.82BCNY
567.92M · vs all stocks (USD)
Updated Aug 20, 2026
Trailing P/E
37.12x
vs Diagnostics & Research peers
Updated Aug 20, 2026
Revenue (TTM)
860.07MCNY
127.74M · vs all stocks (USD)
Updated Aug 20, 2026
Profit Margin
13.28%
vs Diagnostics & Research peers
Updated Aug 20, 2026
Beta
0.8630x
vs all stocks
Updated Aug 20, 2026
52-Week Change
37.75%
vs all stocks
Updated Aug 20, 2026
Forward Annual Dividend Yield
0.30%
vs all stocks
Updated Aug 20, 2026
Market Capitalization
3.82BCNY
567.92M · vs all stocks (USD)
Updated Aug 20, 2026
Enterprise Value
3.25BCNY
482.61M · vs all stocks (USD)
Updated Aug 20, 2026
Trailing P/E
37.12x
vs Diagnostics & Research peers
Updated Aug 20, 2026
Forward P/E
34.05x
vs Diagnostics & Research peers
Updated Aug 20, 2026
Price to Sales (TTM)
4.91x
vs Diagnostics & Research peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 4.45×.Updated Aug 20, 2026
Price to Book (MRQ)
3.30x
vs Diagnostics & Research peers
Updated Aug 20, 2026
Enterprise to Revenue
3.78x
vs Diagnostics & Research peers
Updated Aug 20, 2026
Enterprise to EBITDA
26.37x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 29.26×.Updated Aug 20, 2026
Gross Margin
16.35%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 25.7%.Updated Aug 20, 2026
Profit Margin
13.28%
vs Diagnostics & Research peers
Updated Aug 20, 2026
Operating Margin
8.32%
vs Diagnostics & Research peers
Updated Aug 20, 2026
Return on Assets (TTM)
4.96%
vs Diagnostics & Research peers
Updated Aug 20, 2026
Return on Equity (TTM)
9.28%
vs Diagnostics & Research peers
Updated Aug 20, 2026
Revenue (TTM)
860.07MCNY
127.74M · vs all stocks (USD)
Updated Aug 20, 2026
Revenue per Share (TTM)
10.91CNYUpdated Aug 20, 2026
Quarterly Revenue Growth
10.00%
vs Diagnostics & Research peers
Updated Aug 20, 2026
Gross Profit (TTM)
221.02MCNY
32.83M · vs all stocks (USD)
Updated Aug 20, 2026
EBITDA (TTM)
111.06MCNY
16.50M · vs all stocks (USD)
Updated Aug 20, 2026
Net Income (TTM)
114.23MCNY
16.97M · vs all stocks (USD)
Updated Aug 20, 2026
Quarterly Earnings Growth (YoY)
61.80%
vs Diagnostics & Research peers
Updated Aug 20, 2026
Operating Cash Flow (TTM)
40.17MCNY
5.97M · vs all stocks (USD)
Updated Aug 20, 2026
Levered Free Cash Flow (TTM)
-18.99MCNY
-2.82M · vs all stocks (USD)
Updated Aug 20, 2026
Forward Annual Dividend Rate
0.1600CNYUpdated Aug 20, 2026
Forward Annual Dividend Yield
0.30%
vs all stocks
Updated Aug 20, 2026
Trailing Annual Dividend Rate
0.1480CNYUpdated Aug 20, 2026
Trailing Annual Dividend Yield
0.28%
vs all stocks
Updated Aug 20, 2026
Payout Ratio
11.67%
vs Diagnostics & Research peers
Updated Aug 20, 2026
Revenue
842.50MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
624.56MCNYFY2025 · Dec 31, 2025
Gross Profit
217.95MCNYFY2025 · Dec 31, 2025
Operating Income
134.34MCNY
19.95M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
127.88MCNYFY2025 · Dec 31, 2025
Income Tax Expense
18.24MCNYFY2025 · Dec 31, 2025
Net Income
109.64MCNYFY2025 · Dec 31, 2025
EBIT
128.08MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
159.62MCNYFY2025 · Dec 31, 2025
Research & Development
38.77MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
8.35MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
5.72MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
2.57MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
200.75KCNYFY2025 · Dec 31, 2025
EPS (Basic)
1.38CNYFY2025 · Dec 31, 2025
EPS (Diluted)
1.38CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
79.45MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
79.45MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
109.64MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-19.58MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-27.20MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
467.28MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
109.64MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
-335.40KCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-130.25MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
1.36MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-7.62MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-4.08BCNYFY2025 · Dec 31, 2025
Sale of Investments
4.18BCNYFY2025 · Dec 31, 2025
Other Investing Activity
-89.36MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-2.20MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-13.32MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-41.88MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-55.20MCNYFY2025 · Dec 31, 2025
Shares Outstanding
79.00MSharesUpdated Aug 20, 2026
Float Shares
46.22MSharesUpdated Aug 20, 2026
% Held by Insiders
43.19%
vs all stocks
Updated Aug 20, 2026
% Held by Institutions
21.46%
vs all stocks
Updated Aug 20, 2026
Total Cash (MRQ)
578.72MCNY
85.95M · vs all stocks (USD)
Updated Aug 20, 2026
Total Cash per Share (MRQ)
7.33CNYUpdated Aug 20, 2026
Total Debt (MRQ)
4.37MCNY
649.25K · vs all stocks (USD)
Updated Aug 20, 2026
Total Debt to Equity (MRQ)
0.0034x
vs Diagnostics & Research peers
Updated Aug 20, 2026
Current Ratio (MRQ)
4.99x
vs Diagnostics & Research peers
Updated Aug 20, 2026
Book Value per Share (MRQ)
16.22CNYUpdated Aug 20, 2026
Total Assets
1.54BCNY
229.30M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.32BCNYFY2025 · Dec 31, 2025
Total Liabilities
274.41MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
222.38MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
612.07KCNYFY2025 · Dec 31, 2025
Total Current Liabilities
273.80MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
467.28MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
150.31MCNYFY2025 · Dec 31, 2025
Accounts Receivable
169.47MCNYFY2025 · Dec 31, 2025
Accounts Payable
13.01MCNYFY2025 · Dec 31, 2025
Short-term Debt
3.71MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
22.38MCNYFY2025 · Dec 31, 2025
Long-term Debt
611.39KCNYFY2025 · Dec 31, 2025
Common Stock (Book)
79.00MCNYFY2025 · Dec 31, 2025
Retained Earnings
503.53MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.27BCNY
188.55M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
35.12CNYUpdated Aug 20, 2026
52-Week High
85.00CNYUpdated Aug 20, 2026
52-Week Change
37.75%
vs all stocks
Updated Aug 20, 2026
Beta
0.8630x
vs all stocks
Updated Aug 20, 2026
50-Day MA
46.59CNYUpdated Aug 20, 2026
200-Day MA
53.39CNYUpdated Aug 20, 2026
Avg 10-Day Volume
7.89MSharesUpdated Aug 20, 2026
Avg 30-Day Volume
7.71MSharesUpdated Aug 20, 2026
Diluted EPS (TTM)
1.44CNYUpdated Aug 20, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 16.3%, lower than 95% of its Diagnostics & Research peers (median 51.1%)Significant